Who
Tal Zvi Zaks
Director
Company insider
Files Form 4 as: Director, Teva Pharmaceutical Industries; Director, Adaptimmune Therapeutics; Chief Medical Officer, Moderna.
In numbers
- Trades disclosed
- 562
- Buys
- 0
- Sells
- 75
- Bought
- $0
- Sold
- $124.2M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 29 Nov 2016
- Last trade
- 5 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Aug 2026filed 10 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $59317 at $34.87 | filing |
| 5 Aug 2026filed 10 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $59317 at $34.87 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —14,492 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —14,492 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —14,492 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —14,492 | filing |
| 28 May 2026filed 1 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,242 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,242 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —9,632 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —9,632 | filing |
| 5 Jun 2025filed 9 Jun 2025 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —14,492 at $0.00 | filing |
| 15 Jun 2024filed 17 Jun 2024 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —21,108 at $0.00 | filing |
| 15 Jun 2024filed 17 Jun 2024 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —21,108 | filing |
| 6 Jun 2024filed 10 Jun 2024 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,632 at $0.00 | filing |
| 4 Aug 2023filed 7 Aug 2023 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,810 at $0.00 | filing |
| 4 Aug 2023filed 7 Aug 2023 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —15,810 | filing |
| 15 Jun 2023filed 20 Jun 2023 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —21,108 at $0.00 | filing |
| 4 Nov 2022filed 7 Nov 2022 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,205 at $0.00 | filing |
| 4 Nov 2022filed 7 Nov 2022 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —12,205 | filing |
| 4 Aug 2022filed 8 Aug 2022 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,810 at $0.00 | filing |
News
Teva Pharmaceutical Industries Ltd: UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's DiseaseTEVA · finanznachrichten.de · 20 Oct 2026Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026
0 headlines in the last 90 days name Tal Zvi Zaks; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.